A	0	0
novel	2	6
receptor	8	15
-	17	17
ligand	19	24
pathway	26	32
for	34	36
entry	38	42
of	44	45
Francisella	47	57
tularensis	59	68
in	70	71
monocyte	73	80
-	81	81
like	82	85
THP	87	89
-	90	90
1	91	91
cells	93	97
:	98	98
interaction	100	110
between	112	118
surface	120	126
nucleolin	128	136
and	138	140
bacterial	142	150
elongation	152	161
factor	163	168
Tu	170	171
.	172	172

Francisella	174	184
tularensis	186	195
,	196	196
the	198	200
causative	202	210
agent	212	216
of	218	219
tularemia	221	229
,	230	230
is	232	233
one	235	237
of	239	240
the	242	244
most	246	249
infectious	251	260
human	262	266
bacterial	268	276
pathogens	278	286
.	287	287

It	289	290
is	292	293
phagocytosed	295	306
by	308	309
immune	311	316
cells	318	322
,	323	323
such	325	328
as	330	331
monocytes	333	341
and	343	345
macrophages	347	357
.	358	358

The	360	362
precise	364	370
mechanisms	372	381
that	383	386
initiate	388	395
bacterial	397	405
uptake	407	412
have	414	417
not	419	421
yet	423	425
been	427	430
elucidated	432	441
.	442	442

Participation	444	456
of	458	459
C3	461	462
,	463	463
CR3	465	467
,	468	468
class	470	474
A	476	476
scavenger	478	486
receptors	488	496
and	498	500
mannose	502	508
receptor	510	517
in	519	520
bacterial	522	530
uptake	532	537
have	539	542
been	544	547
already	549	555
reported	557	564
.	565	565

However	567	573
,	574	574
contribution	576	587
of	589	590
an	592	593
additional	595	604
,	605	605
as	607	608
-	609	609
yet	610	612
-	613	613
unidentified	614	625
receptor	627	634
for	636	638
F	640	640
.	641	641
tularensis	643	652
internalization	654	668
has	670	672
been	674	677
suggested	679	687
.	688	688

We	690	691
show	693	696
here	698	701
that	703	706
cell	708	711
-	712	712
surface	713	719
expressed	721	729
nucleolin	731	739
is	741	742
a	744	744
receptor	746	753
for	755	757
Francisella	759	769
tularensis	771	780
Live	782	785
Vaccine	787	793
Strain	795	800
(	802	802
LVS	803	805
)	806	806
and	808	810
promotes	812	819
LVS	821	823
binding	825	831
and	833	835
infection	837	845
of	847	848
human	850	854
monocyte	856	863
-	864	864
like	865	868
THP	870	872
-	873	873
1	874	874
cells	876	880
.	881	881

The	883	885
HB	887	888
-	889	889
19	890	891
pseudopeptide	893	905
that	907	910
binds	912	916
specifically	918	929
carboxy	931	937
-	938	938
terminal	939	946
RGG	948	950
domain	952	957
of	959	960
nucleolin	962	970
inhibits	972	979
LVS	981	983
binding	985	991
and	993	995
infection	997	1005
of	1007	1008
monocyte	1010	1017
-	1018	1018
like	1019	1022
THP	1024	1026
-	1027	1027
1	1028	1028
cells	1030	1034
.	1035	1035

In	1037	1038
a	1040	1040
pull	1042	1045
-	1046	1046
down	1047	1050
assay	1052	1056
,	1057	1057
elongation	1059	1068
factor	1070	1075
Tu	1077	1078
(	1080	1080
EF	1081	1082
-	1083	1083
Tu	1084	1085
)	1086	1086
,	1087	1087
a	1089	1089
GTP	1091	1093
-	1094	1094
binding	1095	1101
protein	1103	1109
involved	1111	1118
in	1120	1121
protein	1123	1129
translation	1131	1141
,	1142	1142
usually	1144	1150
found	1152	1156
in	1158	1159
cytoplasm	1161	1169
,	1170	1170
was	1172	1174
recovered	1176	1184
among	1186	1190
LVS	1192	1194
bacterial	1196	1204
membrane	1206	1213
proteins	1215	1222
bound	1224	1228
on	1230	1231
RGG	1233	1235
domain	1237	1242
of	1244	1245
nucleolin	1247	1255
.	1256	1256

A	1258	1258
specific	1260	1267
polyclonal	1269	1278
murine	1280	1285
antibody	1287	1294
was	1296	1298
raised	1300	1305
against	1307	1313
recombinant	1315	1325
LVS	1327	1329
EF	1331	1332
-	1333	1333
Tu	1334	1335
.	1336	1336

By	1338	1339
fluorescence	1341	1352
and	1354	1356
electron	1358	1365
microscopy	1367	1376
experiments	1378	1388
,	1389	1389
we	1391	1392
found	1394	1398
that	1400	1403
a	1405	1405
fraction	1407	1414
of	1416	1417
EF	1419	1420
-	1421	1421
Tu	1422	1423
could	1425	1429
be	1431	1432
detected	1434	1441
at	1443	1444
the	1446	1448
bacterial	1450	1458
surface	1460	1466
.	1467	1467

Anti	1469	1472
-	1473	1473
EF	1474	1475
-	1476	1476
Tu	1477	1478
antibodies	1480	1489
reduced	1491	1497
LVS	1499	1501
binding	1503	1509
to	1511	1512
monocyte	1514	1521
-	1522	1522
like	1523	1526
THP	1528	1530
-	1531	1531
1	1532	1532
cells	1534	1538
and	1540	1542
impaired	1544	1551
infection	1553	1561
,	1562	1562
even	1564	1567
in	1569	1570
absence	1572	1578
of	1580	1581
complement	1583	1592
and	1594	1596
complement	1598	1607
receptors	1609	1617
.	1618	1618

Interaction	1620	1630
between	1632	1638
EF	1640	1641
-	1642	1642
Tu	1643	1644
and	1646	1648
nucleolin	1650	1658
was	1660	1662
illustrated	1664	1674
by	1676	1677
two	1679	1681
different	1683	1691
pull	1693	1696
-	1697	1697
down	1698	1701
assays	1703	1708
using	1710	1714
recombinant	1716	1726
EF	1728	1729
-	1730	1730
Tu	1731	1732
proteins	1734	1741
and	1743	1745
either	1747	1752
RGG	1754	1756
domain	1758	1763
of	1765	1766
nucleolin	1768	1776
or	1778	1779
cell	1781	1784
solubilized	1786	1796
nucleolin	1798	1806
.	1807	1807

Altogether	1809	1818
,	1819	1819
our	1821	1823
results	1825	1831
demonstrate	1833	1843
that	1845	1848
the	1850	1852
interaction	1854	1864
between	1866	1872
surface	1874	1880
nucleolin	1882	1890
and	1892	1894
its	1896	1898
bacterial	1900	1908
ligand	1910	1915
EF	1917	1918
-	1919	1919
Tu	1920	1921
plays	1923	1927
an	1929	1930
important	1932	1940
role	1942	1945
in	1947	1948
Francisella	1950	1960
tularensis	1962	1971
adhesion	1973	1980
and	1982	1984
entry	1986	1990
process	1992	1998
and	2000	2002
may	2004	2006
therefore	2008	2016
facilitate	2018	2027
invasion	2029	2036
of	2038	2039
host	2041	2044
tissues	2046	2052
.	2053	2053

Since	2055	2059
phagosomal	2061	2070
escape	2072	2077
and	2079	2081
intra	2083	2087
-	2088	2088
cytosolic	2089	2097
multiplication	2099	2112
of	2114	2115
LVS	2117	2119
in	2121	2122
infected	2124	2131
monocytes	2133	2141
are	2143	2145
very	2147	2150
similar	2152	2158
to	2160	2161
those	2163	2167
of	2169	2170
human	2172	2176
pathogenic	2178	2187
F	2189	2189
.	2190	2190
tularensis	2192	2201
ssp	2203	2205
tularensis	2207	2216
,	2217	2217
the	2219	2221
mechanism	2223	2231
of	2233	2234
entry	2236	2240
into	2242	2245
monocyte	2247	2254
-	2255	2255
like	2256	2259
THP	2261	2263
-	2264	2264
1	2265	2265
cells	2267	2271
,	2272	2272
involving	2274	2282
interaction	2284	2294
between	2296	2302
EF	2304	2305
-	2306	2306
Tu	2307	2308
and	2310	2312
nucleolin	2314	2322
,	2323	2323
might	2325	2329
be	2331	2332
similar	2334	2340
in	2342	2343
the	2345	2347
two	2349	2351
subspecies	2353	2362
.	2363	2363

Thus	2365	2368
,	2369	2369
the	2371	2373
use	2375	2377
of	2379	2380
either	2382	2387
nucleolin	2389	2397
-	2398	2398
specific	2399	2406
pseudopeptide	2408	2420
HB	2422	2423
-	2424	2424
19	2425	2426
or	2428	2429
recombinant	2431	2441
EF	2443	2444
-	2445	2445
Tu	2446	2447
could	2449	2453
provide	2455	2461
attractive	2463	2472
therapeutic	2474	2484
approaches	2486	2495
for	2497	2499
modulating	2501	2510
F	2512	2512
.	2513	2513
tularensis	2515	2524
infection	2526	2534
.	2535	2535
